Popular Articles
-
OCT Companies in the News
(45 articles) LightLab Imaging
(42 articles) Axsun Technologies
(34 articles) Michelson Diagnostics
-
Organizations in the News
(10 articles) Lawrence Livermore National Laboratory
(9 articles) Massachusetts Institute of Technology
(8 articles) Food and Drug Administration
(7 articles) Thoraxcenter at Erasmus University Medical Center
(5 articles) University of Florida
(4 articles) Cardiovascular Research Foundation
(3 articles) University College Hospital
-
Abbott Announces Positive Data From Absorb Trial on Its Bioresorbable Vascular Scaffold Technology
Explore Article PR Newswire (Mar 15 2010) Cardiology , Other Business News
e ABSORB trial is a prospective, non-randomized (open label), two-phase study that enrolled 131 patients from Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety – MACE and treated site thrombosis rates – at 30 days; six, nine, 12, 18 and 24 months; with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioresorbable vascular scaffold, including successful deployment of the system. Other key endpoints of the study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence ...Comment on Article Mentions: Patrick W. Serruys Thoraxcenter at Erasmus University Medical Center
-
Volcano Announces Activities at the ACC 2010
Explore Article ptca.org (Mar 12 2010) Cardiology , Other Business News
March 11, 2010 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today its participation in the Annual Scientific Sessions of the American College of Cardiology (ACC) Conference from March 14th to March 16th in Atlanta, GA. "The Percutaneous Coronary Intervention (PCI) procedures that benefit from our technology are very complex, often involving multi-vessel disease, bifurcations, left mains, chronic total occlusions, intermediate lesions, or various combinations," commented Joe Burnett, Executive Vice President at Volcano. "Our message, ...Comment on Article Mentions: GE Healthcare Siemens Volcano
-
Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems
Explore Article PR Newswire (Mar 12 2010) Cardiology , Other Business News
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today its Fractional Flow Reserve (FFR) technology can now integrate with the FFR modules of hemodynamic monitoring systems from GE, Siemens, McKesson, and Mennen. "Utilization of Volcano's physiology (functional measurement) products has grown 79% in the last year, driven primarily by the landmark FAME data and recent elevation of the level of evidence for FFR in the ACC/AHA/SCAI PCI Guidelines to Level A," commented Scott ...Comment on Article Mentions: GE Healthcare Siemens Volcano
-
Volcano Corporation 10-K SEC Filing
Explore Article sec.gov (Mar 9 2010) Cardiology , Other Business News
The court has ordered the damages trial to commence on March 22, 2010. The court requested that the parties propose an appropriate modification to the terms of the existing preliminary injunction, but no revised preliminary injunction has been entered by the court. We intend to appeal the jury verdict and are not in the position to estimate the possible loss attributable to this verdict. We may be a party to various claims in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred and were not material in any period reported. Additionally, ... -
Volcano Corporation Secondary Offering of ~ 1.2M Shares Current Market Cap ~ $1.2B
Explore Article 24/7 Wall St. (Mar 9 2010) Cardiology , Other Business News
offering below. Comerica Incorporated (NYSE: CMA) is down 2% at $35.58 right after the open on 5.4 million shares. Average volume here is only 2.45 million shares. Comerica sold $800 million via 22,857,143 shares of common stock at $35.00 per share to repay the TARP. Its market cap is 5.4 billion and the 52-week range is $11.91 to $37.32. Susquehanna Bancshares, Inc. (NASDAQ: SUSQ) is also paying off the TARP… or is it the TRAP? The company announced last night that it was offering $300 million in common stock and $50 million in Cumulative Trust Preferred securities. Shares are down ...
Comment on Article Mentions: Volcano
-
Volcano Corporation Presentation at Roth Capital Partners Conference to be Webcast
Explore Article PR Newswire (Mar 9 2010) Cardiology , Other Business News
SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the 22nd Annual Roth OC Growth Stock Conference on Tuesday, March 16. The presentation by John Dahldorf, chief financial officer, will begin at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time). The presentation will be available through the conference website at http://www.wsw.com/webcast/roth23/volc/ and via the company's website at www.volcanocorp.com. Volcano Corporation (Nasdaq: VOLC) offers a broad ...Comment on Article Mentions: Volcano John Dahldorf
-
Stentys self-expanding stent receives CE Marking to treat acute coronary syndrome (ACS)
Explore Article pcronline.com (Mar 5 2010) Cardiology , Other Business News
PRINCETON, N.J., and PARIS, March 5, 2010-Medical device pioneer Stentys announced today that it has received CE Marking for its self-expanding and disconnectable stent to treat acute coronary syndrome (ACS). The self-expanding feature of the Stentys platform, unrivaled in the stent industry, is designed to ensure optimal apposition of a stent in the critical initial hours and days after an acute myocardial infarction (AMI) procedure, by being continuously applied to the vessel's internal surface even during thrombus and vessel spasm relief-thereby avoiding malapposition, a significant concern to cardiologists. "For European regulatory approval we have demonstrated how the Stentys stent perfectly ... -
Signatec Data Acquisition and Playback Systems Sustain 2.8 GB/s With No Data Loss
Explore Article prweb.com (Mar 5 2010) Other Business News
Signatec Inc. today released its DR2800 signal recording system platform capable of sustaining 2.8 GB/s of data recording directly to a high-speed RAID system. Ideally suited for the Synthetic Aperture Radar (SAR), Wideband Flight Recorder and advanced Optical Coherence Tomography (OCT) industries, the DR2800 platform’s industry-leading data recording rate is achieve by combining two or more of Signatec’s PCI Express (PCIe)-based high speed analog signal digitizers to continuously record 2800 MB/s of 8-bit or 14-bit data for the entire 6 to 96 TB RAID volume with no breaks in the signal record.
-
Volcano revenue rises, but bottom line shrinks
Explore Article sacbee.com (Mar 5 2010) Cardiology , Other Business News
San Diego-based medical equipment maker Volcano Corp., which operates a manufacturing facility in Rancho Cordova, saw sizable revenue gains in 2009 but posted losses for the final quarter and year. The company reported revenue of $71 million for the quarter ended Dec. 31, up 44 percent from $49.3 million in the year-ago period. The company said revenue was boosted by $5.8 million from Axsun Technologies Inc., which Volcano acquired in the fourth quarter of 2008. Still, Volcano lost $12.1 million, or 25 cents a share, in the final quarter, compared with earnings of $1.4 million, or 3 cents a share, ...Comment on Article Mentions: Axsun Technologies Volcano
-
Functional Measurement Functioning Well at Volcano
Explore Article ptca.org (Mar 3 2010) Cardiology , Other Business News
To stent or not to stent? The question is more than a rhetorical one when a patient is on the cath lab table and a coronary blockage is seen on the angiogram. Luckily, there are methods available to help give a more scientific answer to this question. Equipment for two of these techniques, Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR -- a.k.a. "functional measurement") is manufactured by Volcano Corporation (Nasdaq: VOLC) a San Diego-based device company that announced its fourth quarter results earlier today.
Comment on Article Mentions: Volcano
-
Volcano Slips To Loss In Q4; Provides FY10 Outlook
Explore Article RTTNews (Mar 3 2010) Cardiology , Other Business News
Volcano Corporation (VOLC: News ) reported a fourth-quarter net loss of $12.07 million or $0.25 per share compared to profit of $1.36 million or $0.03 per share last year. Non-GAAP net income increased to $6.96 million or $0.14 per share from $4.17 million or $0.08 per share last year. On average, 10 analysts polled by Thomson Reuters expected the company to report a loss of $0.02 per share for the quarter. Analysts' estimates typically exclude special items. Revenues increased to $71.01 million from $49.25 million a year ago. Analysts expected revenue of $68.37 million for the quarter
Comment on Article Mentions: Volcano
-
Volcano Reports 44 Percent Increase in Fourth Quarter Revenues
Explore Article PR Newswire (Mar 3 2010) Cardiology , Other Business News
SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues for the quarter ended December 31, 2009, were $71.0 million, an increase of 44 percent versus revenues of $49.3 million in the fourth quarter a year ago. Revenues for the fourth quarter of 2009 included $5.8 million from Axsun Technologies, Inc., which Volcano acquired in the fourth quarter of 2008, and contributed $578,000 in revenues in the fourth quarter a year ago. ...
Comment on Article Mentions: Axsun Technologies Volcano Scott Huennekens
-
Cement not included – 10:1 return on investment from federal infrastructure investment in photonics
Explore Article Optical Coherence Tomography News (Mar 3 2010) Other Business News
Responding to the credit crisis and resulting global recession, national governments around the world are furiously pumping cement-truck loads of money into infrastructure projects. Some of these economic stimulus initiatives will work, some will fail, and few will offer a specific Return On Investment (ROI). Roads, bridges buildings and last generation manufacturing jobs are important – and easy to justify in a political context. Yet building a next generation of successful “cement not included” innovation companies will in turn generate long-term jobs, exports, tax bases, and ultimately pay the tab on the short-term stimulus spends.
Comment on Article Mentions: National Research Council Canada
-
Michelson Diagnostics Reports First Quantitative Results on Cancer Diagnosis Using Multi-beam OCT imaging
Explore Article Optical Coherence Tomography News (Mar 2 2010) Oncology , Other Business News
(Orpington, UK) March 2, 2010 -- The first quantitative results from a study on the use of multi-beam OCT imaging for oral cancer diagnosis have been announced at the 2nd Scientific Meeting of the Head and Neck Optical Diagnostics Society (HNODS), held in San Francisco, 23-24 Januar
Comment on Article Mentions: Michelson Diagnostics Jon Holmes Michelson Diagnostics EX1301
-
Supporting New Ideas, New Discoveries And Jobs In Waterloo Region McGuinty Government Boosts World-Leading Research
Explore Article Daily Exchange (Mar 1 2010) Ophthalmology , Other Business News
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Developing instruments to combat an epidemic of vision loss Lead researcher: Dr. Christopher Hudson Provincial funding: $2,478,074 Number of researchers affected: 9 Key private sector partners: Photon etc. Inc., Optovue Inc.Comment on Article Mentions: Optovue University of Waterloo
RSS Feed
Recent Comments
Eric Swanson » Jim Fujimoto video: Biophotonics and optical coherence tomography
Great video Jim!
dariemihaela » Gary S. Mintz
Dear Prof. Dr. Gary S. Mintz, You are an extraordinary expert in imaging, an intelligence ...
See all recent comments